Abstract |
The efficacy of cyclophosphamide (CY) in the treatment of severe systemic vasculitis has been demonstrated, but its optimal administration regimen remains to be defined. The four patients described participated in prospective therapeutic trials of polyarteritis nodosa (PAN) without hepatitis B infection markers, Churg-Strauss syndrome (CSS) and Wegener's granulomatosis (WG) and received daily oral low-dose CY after failure of a monthly pulse regimen. These patients were included in this study because of failure to induce clinical remission (two patients) and relapse during the course of treatment (two patients). The results were good with initial clinical remission in three patients and stabilization in one. One patient with WG relapsed 10 months after changing therapeutics. The advantages of the different administration protocols are discussed.
|
Authors | T Généreau, O Lortholary, P Leclerq, D Grenet, M Tubéry, D Sicard, I Caubarrère, L Guillevin |
Journal | British journal of rheumatology
(Br J Rheumatol)
Vol. 33
Issue 10
Pg. 959-62
(Oct 1994)
ISSN: 0263-7103 [Print] England |
PMID | 7921758
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Steroids
- Cyclophosphamide
|
Topics |
- Administration, Oral
- Aged
- Churg-Strauss Syndrome
(drug therapy)
- Cyclophosphamide
(administration & dosage)
- Drug Administration Schedule
- Female
- Granulomatosis with Polyangiitis
(drug therapy)
- Humans
- Injections, Intravenous
- Male
- Middle Aged
- Polyarteritis Nodosa
(drug therapy)
- Prospective Studies
- Steroids
(administration & dosage)
- Treatment Outcome
|